Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters. EBITDA margins in AP cluster expected to improve from 26% in Q2 FY25 to about 30% in 2-3 years post oncology and mother & child care additions by FY26-FY27.
From Krishna Institute of Medical Sciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters.
- Telangana cluster, including Sunshine and Kondapur facilities, has significant ramp-up potential with additional beds and higher occupancy.
- AP cluster margins expected to improve from 26% to around 30% over 2-3 years with oncology and mother & child care additions.
- Nashik hospital expected to break even by 2Q/3Q FY26, with doctor onboarding completing by March 2025.
- Karnataka and Kerala clusters are growth focuses, planning to scale up to 2,000 beds in Bangalore and 2,500-3,000 beds in Kerala over time.
- International patient revenue in Telangana targeted to increase from INR 40-50 crores to INR 100-150 crores over time; Bangalore and Thane expected to contribute more.
2 more points from Krishna Institute of Medical Sciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Krishna Institute of Medical Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company’s CAPEX guidance for FY 2026 remains around INR 500-600 crores, in line with previous estimates.
- Ongoing capital expenditures are on track with sanctioned facilities, mainly for bed expansions and new hospitals.
- Major projects include adding 500 beds at Kondapur (Telangana cluster) expected next financial year.
- New hospitals are planned in Karnataka (including Sarjapur and northern Bangalore) and Kerala, aiming to scale to around 2,000 beds in Bangalore and 2,500-3,000 beds in Kerala over time.
- Construction on new hospitals in Karnataka will start early next year with a 3-4 year commissioning timeline.
2 more points from Krishna Institute of Medical Sciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Krishna Institute of Medical Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Krishna Institute of Medical Sciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Krishna Institute of Medical Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.1K Cr, net profit ₹33 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krishna Institute of Medical Sciences Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
- 3B Blackbio (Q3 FY25)
Consolidated Revenue from Operations Q3 FY 2024-25: ₹2,539.25 Lakh vs ₹1,766.89 Lakh in Q3 FY 2023-24 (↑ approx. Key concall takeaways from 3B Blackbio DX…
- Rainbow Childrens Medicare Ltd (Q3 FY25)
Mature hospitals show approximately 9% inpatient (IP) volume growth on a like-to-like basis. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
- Dr Lal Pathlabs (Q3 FY25)
Swasthfit (bundle test program) continues strong growth (27.2% in Q3 FY25), with plans to expand market penetration beyond Tier-1 and Tier-2 cities. Key…
Arthneeti Pro · Annual
Krishna Institute of Medical Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krishna Institute of Medical Sciences Ltd Q3 FY25 results?
Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters. EBITDA margins in AP cluster expected to improve from 26% in Q2 FY25 to about 30% in 2-3 years post oncology and mother & child care additions by FY26-FY27.
What is Krishna Institute of Medical Sciences Ltd share price analysis?
Krishna Institute of Medical Sciences Ltd currently shows a neutral. The stock trades at a P/E of 161.5 with a market cap of ₹33,691 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krishna Institute of Medical Sciences Ltd planning capital expenditure?
The company’s CAPEX guidance for FY 2026 remains around INR 500-600 crores, in line with previous estimates.
Keep Krishna Institute of Medical Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.